LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb. 3, 2004--BioSante Pharmaceuticals, Inc. (Amex:BPA) reiterated today its Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Medical Research Institute of Infectious Diseases for the development of a needle-free vaccine against ricin, a poisonous substance thought to have been detected in a U.S. Senate mailroom this week. BioSante has provided BioVant(TM), its proprietary nanoparticulate-based vaccine adjuvant and delivery system, and the Army has provided recombinant antigens to be used in potential vaccines against various bioterrorism agents.
The CRADA biodefense agreement was previously announced in June 2003, and also includes the development of needle-free vaccines for anthrax, staph and bubonic plague. BioVant utilizes BioSante’s proprietary calcium phosphate (CAP) nanotechnology to administer vaccines through the mucus membranes of the mouth or nasal passages, allowing the development of oral or inhaled vaccines.
About BioSante Pharmaceuticals, Inc.
BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its calcium phosphate nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems. Additional information is available online at www.biosantepharma.com.
Contacts
BioSante Pharmaceuticals, Inc. Phil Donnenberg, 847-478-0500 x 101 or
Andrew Huff, 847-382-7404
